title: Multiple sclerosis drugs: how much bang for the buck?
authors.affiliation: Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX 75216, USA; Department of Neurology and Neurotherapeutics University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany. Electronic address: olaf.stuve@utsouthwestern.edu.
authors.forename: Olaf
authors.initials: O
authors.lastname: Stüve
authors.affiliation: Department of Biostatistics, Section on Research Methods and Clinical Trials, University of Alabama at Birmingham, AL, USA.
authors.forename: Gary R
authors.initials: GR
authors.lastname: Cutter
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D010455:Peptides; D016899:Interferon-beta